These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 22272912)

  • 1. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
    Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
    Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk in rheumatoid arthritis.
    Nurmohamed MT
    Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
    van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
    Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.
    Cugno M; Ingegnoli F; Gualtierotti R; Fantini F
    Curr Vasc Pharmacol; 2010 Mar; 8(2):285-92. PubMed ID: 19485909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic inflammation increases the risk of cardiovascular disease in patients with rheumatoid arthritis].
    Troelsen LN; Jacobsen S
    Ugeskr Laeger; 2006 Sep; 168(39):3304-8. PubMed ID: 17032593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
    Dixon WG; Symmons DP
    Ann Rheum Dis; 2007 Sep; 66(9):1132-6. PubMed ID: 17251223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis.
    Mahmoudi M; Aslani S; Fadaei R; Jamshidi AR
    Int J Rheum Dis; 2017 Mar; 20(3):287-297. PubMed ID: 28205331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
    Fragoulis GE; Panayotidis I; Nikiphorou E
    Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the cardiovascular disease burden in rheumatoid arthritis.
    Van Doornum S; Jennings GL; Wicks IP
    Med J Aust; 2006 Mar; 184(6):287-90. PubMed ID: 16548834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
    Avouac J; Allanore Y
    Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities.
    Arida A; Protogerou AD; Konstantonis G; Fragiadaki K; Kitas GD; Sfikakis PP
    Rheumatology (Oxford); 2017 Jun; 56(6):934-939. PubMed ID: 28160488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation.
    Miller AM; McInnes IB
    Curr Pharm Des; 2011; 17(1):1-8. PubMed ID: 21222645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy.
    Mellana WM; Aronow WS; Palaniswamy C; Khera S
    Curr Pharm Des; 2012; 18(11):1450-6. PubMed ID: 22364129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
    Puttevils D; De Vusser P; Geusens P; Dens J
    Acta Cardiol; 2014 Apr; 69(2):111-8. PubMed ID: 24783461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk in systemic inflammatory diseases].
    Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
    G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?
    Pieringer H; Pichler M; Pohanka E; Hoppe UC
    Curr Pharm Des; 2014; 20(4):486-95. PubMed ID: 23565635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis.
    Giles JT; Post W; Blumenthal RS; Bathon JM
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):320-9. PubMed ID: 16932711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
    Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
    Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
    Giles JT
    Curr Rheumatol Rep; 2016 May; 18(5):27. PubMed ID: 27032790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.